Article Synopsis
- Randomized double-blind trials show that probiotics can boost HDL levels and lower the risk of heart disease in end-stage renal disease (ESRD) patients.
- Meta-analyses suggest that higher HDL levels positively influence ESRD outcomes, reinforcing the importance of cholesterol management.
- Probiotics enhance HDL production through a specific metabolic pathway, highlighting a new approach for reducing cardiovascular risks in ESRD patients.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Randomized double-blind trials have shown that probiotic mixtures significantly increase high-density lipoprotein (HDL) levels and reduce the risk of cardiovascular disease mortality in end-stage renal disease (ESRD) patients. Meta-analysis with prospective cohort studies further confirms that elevated HDL is a protective factor for ESRD outcomes. In severe renal injury models, including 5/6 nephrectomy and apolipoprotein E-deficient ( ) mice, probiotics restored cardiac function, mirroring the cardioprotective effects seen in humans. Mechanistic studies indicate that probiotics enhance intestinal HDL3 production through the insulin-mediated SP1(P)-CYP27A-LXRα/β-ABCA1 pathway, thereby maintaining HDL metabolic homeostasis. This study reveals a novel link between probiotic intervention and host cholesterol metabolism, offering a previously unexplored strategy for reducing cardiovascular risk in ESRD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371253 | PMC |
| http://dx.doi.org/10.1002/imt2.70062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral anticoagulant therapy for patients with atrial fibrillation on long-term dialysis: A network meta-analysis of 137,574 patients.
Eur J Clin Invest
September 2025
Liverpool Centre for Cardiovascular Science, at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Background: Patients with atrial fibrillation (AF) with end-stage renal failure on renal replacement therapy are at high risk of stroke and bleeding, but the optimal oral anticoagulation (OAC) strategy is uncertain. To investigate the most effective OAC therapy for patients with AF on long-term dialysis.
Methods: PubMed, EMBASE and Web of Science databases were systematically searched from inception to 9 October 2024 to identify relevant studies on OAC strategy for patients with AF on long-term dialysis.
Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease.
Clin Kidney J
September 2025
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, effectively treat resistant hypertension, reduce proteinuria and lower mortality in heart failure with reduced ejection fraction. However, their long-term effects in chronic kidney disease (CKD) remain unclear. This study investigated spironolactone's impact on end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hyperkalemia and mortality in CKD patients.
View Article and Find Full Text PDFA Tale of Overlapping Autoimmune Serologies: Diagnosing Hydralazine-Induced Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Related With Isolated Pulmonary Involvement.
Cureus
August 2025
Norton College of Medicine, SUNY Upstate Medical University, Syracuse, USA.
Hydralazine is an antihypertensive that can induce immune-related adverse effects, such as hydralazine-induced lupus and hydralazine-induced antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV involves necrotizing inflammation of small blood vessels, manifesting as fever, malaise, arthralgia, and myalgia, potentially leading to organ failure. Diagnosis includes clinical evaluation, serological testing for ANCA, and histopathological examination, confirmed by necrotizing granulomatous inflammation in affected tissues.
View Article and Find Full Text PDFAzithromycin-Induced Stevens-Johnson Syndrome in a Patient With SARS-CoV-2 and End-Stage Renal Disease.
Cureus
August 2025
Internal Medicine, University of Maryland School of Medicine, Baltimore, USA.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are a spectrum of immune-mediated mucocutaneous injuries often due to an adverse reaction to medication or infection. Numerous medications have been associated with SJS, with abacavir, allopurinol, aromatic antiepileptic drugs, minocycline, proton pump inhibitors, and sulfasalazine being the most common. Additionally, there have been several case reports of SJS associated with SARS-CoV-2 infection.
View Article and Find Full Text PDFTriple Serosal Involvement in End-Stage Renal Disease (ESRD): A Case of Atypical Uremic Polyserositis With Elevated Serum-Ascites Albumin Gradient and Alkaline Phosphatase.
Cureus
August 2025
Department of Nephrology, Texas Tech University Health Sciences Center, Odessa, USA.
Uremic polyserositis is a rare and often underdiagnosed manifestation of end-stage renal disease (ESRD), typically characterized by concurrent or sequential inflammation of multiple serosal membranes. We report a diagnostically challenging case of a 40-year-old woman with ESRD on intermittent hemodialysis who presented with dyspnea following a missed dialysis session. Imaging revealed bilateral pleural effusions, a moderate-to-large pericardial effusion, and ascites.
View Article and Find Full Text PDF